NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 313 filers reported holding NOVOCURE LTD in Q1 2022. The put-call ratio across all filers is 1.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $282 | +4.8% | 18 | 0.0% | 0.00% | – |
Q4 2023 | $269 | -77.6% | 18 | -10.0% | 0.00% | – |
Q1 2023 | $1,203 | -18.0% | 20 | 0.0% | 0.00% | – |
Q4 2022 | $1,467 | -26.6% | 20 | 0.0% | 0.00% | – |
Q3 2022 | $2,000 | +100.0% | 20 | 0.0% | 0.00% | – |
Q2 2022 | $1,000 | -90.0% | 20 | -83.3% | 0.00% | – |
Q1 2022 | $10,000 | +233.3% | 120 | +200.0% | 0.00% | – |
Q4 2021 | $3,000 | -50.0% | 40 | -20.0% | 0.00% | – |
Q3 2021 | $6,000 | -45.5% | 50 | 0.0% | 0.00% | – |
Q2 2021 | $11,000 | -8.3% | 50 | -44.4% | 0.00% | – |
Q1 2021 | $12,000 | -36.8% | 90 | -18.2% | 0.00% | -100.0% |
Q4 2020 | $19,000 | +11.8% | 110 | -26.7% | 0.00% | 0.0% |
Q3 2020 | $17,000 | -15.0% | 150 | -54.5% | 0.00% | 0.0% |
Q2 2020 | $20,000 | -9.1% | 330 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $22,000 | +100.0% | 330 | +153.8% | 0.00% | 0.0% |
Q4 2019 | $11,000 | +10.0% | 130 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $10,000 | – | 130 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |